Myriad Genetics (MYGN) Non-Current Debt (2020 - 2026)

Myriad Genetics (MYGN) has 5 years of Non-Current Debt data on file, last reported at $120.3 million in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $120.3 million, up 102.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $120.3 million (up 102.87% YoY), and the FY2025 annual result was $119.9 million, up 202.78% from the prior year.
• Non-Current Debt steadied at $120.3 million in Q1 2026 per MYGN's latest filing, from $119.9 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $120.3 million in Q1 2026 and troughed at $38.4 million in Q2 2023.
• A 4-year average of $62.8 million and a median of $39.0 million in 2024 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2024 and 2025: Non-Current Debt climbed 1.04% in 2024, then jumped 206.41% in 2025.
• A 4-year view of Non-Current Debt shows it stood at $38.5 million in 2023, then climbed by 2.86% to $39.6 million in 2024, then jumped by 202.78% to $119.9 million in 2025, then increased by 0.33% to $120.3 million in 2026.
• Business Quant data shows MYGN's Non-Current Debt at $120.3 million in Q1 2026, $119.9 million in Q4 2025, and $119.5 million in Q3 2025.